HI-Bio
Michele Anderson is an accomplished professional in regulatory affairs with extensive experience in the biopharmaceutical industry. Currently serving as Head of Regulatory Affairs and Senior Vice President at HI-Bio, a Biogen Company since July 2023, Michele previously held the position of Chief Development Officer at Assembly Biosciences, Inc., from November 2019 to July 2023, overseeing clinical development for HBV and Herpes programs. Prior to that, Michele worked at Gilead Sciences for a decade, advancing through roles such as Executive Director and Senior Director, leading regulatory affairs in liver diseases, inflammation, and oncology. Michele's earlier roles include Senior Manager at CV Therapeutics, where responsibilities included regulatory support for the NDA of Lexiscan, and Manager at IMPAX Laboratories, focusing on abbreviated new drug applications. Michele holds a BS in Biological Sciences from California Polytechnic State University-San Luis Obispo.
This person is not in any teams
HI-Bio
HI-Bio was established on the premise that treatments for immune-mediated illnesses have the potential to provide patients with better outcomes. Many IMDs are caused by immune system cells, such as mast cells, neutrophils, plasma cells, and more, which are dysfunctional. These cells are in charge of crucial processes and functions. With the useof medicines, HI-efforts Bio uses a precision medicine strategy to target, modify or deplete key cellular disease drivers.HI-Bio was established in 2021 in San Francisco, California.